Prediction and analysis of HLA-A2/A24-restricted cytotoxic T-lymphocyte epitopes of the tumor antigen MAGE-n using the artificial neural networks method on NetCTL1.2 Server

Zhang,Xiu-Min; Huang,Yang; Li,Zeng-Shan; Lin,Hui; Sui,Yan-Fang

doi:10.3892/ol.2010.193

Prediction and analysis of HLA-A2/A24-restricted cytotoxic T-lymphocyte epitopes of the tumor antigen MAGE-n using the artificial neural networks method on NetCTL1.2 Server

Authors:
- Xiu-Min Zhang
- Yang Huang
- Zeng-Shan Li
- Hui Lin
- Yan-Fang Sui
View Affiliations

Affiliations: State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, Department of Emergency Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China
Published online on: September 23, 2010 https://doi.org/10.3892/ol.2010.193
Pages: 1097-1100

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer immunotherapy has become one of the most important therapeutic approaches to cancer in the past two decades. Tumor antigen-derived peptides have been widely used to elicit tumor-specific cytotoxic T lymphocytes (CTLs). Antigen-specific CTLs induced by MAGE-derived peptides have proven to be highly efficacious in the prevention and treatment of various types of tumor. MAGE-n is a new member of the MAGE gene family and has been shown to be closely associated with hepatocellular carcinoma. It is highly homologous to the MAGE-A gene subfamily, particularly to MAGE-3 (93%). MAGE-n-derived peptide QLVFGIEVV is a novel HLA-A2.1-restricted CTL epitope that induces MAGE-n-specific CTLs in vitro. Identification of these CTL epitopes may lead to clinical applications of these peptides as cancer vaccines for patients with MAGE-n+/HLA-A2+ tumors. In the present study, HLA-A/A24-restricted CTL epitopes of antigen MAGE-n were predicted using the NetCTL1.2 Server on the web, COMB >0.85. The results showed that the NetCTL1.2 Server prediction method improved prediction efficacy and accuracy. Additionally, 8 HLA-A2- and 9 HLA-A24-restricted CTL epitope candidates (nonamers) derived from the tumor antigen MAGE-n were predicted. These nonamers, following identification via experimentation, may contribute to the development of potential antigen peptide tumor vaccines.

View Figures

View References

1	Katsura F, Eura M, Chikamatsu K, Oiso M, Yumoto E and Ishikawa T: Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24. Jpn J Clin Oncol. 30:117–121. 2000. View Article : Google Scholar : PubMed/NCBI
2	Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T and van der Bruggen P: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2:167–175. 1995. View Article : Google Scholar : PubMed/NCBI
3	Renkvist N, Castelli C, Robbins PF and Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 50:3–15. 2001. View Article : Google Scholar : PubMed/NCBI
4	Wu W, Sui YF, Ye J, Li ZS, Guo AL, Yang XW, QU P and Zhang XM: The cloning of tumor-associated gene MAGE in human hepatocellular carcinoma cell line. Chin J Cell Mol Immunol. 18:270–274. 2002.
5	Ming LH, Zhu YR, Harris CC, Wang XH, Wu ZY and Sun ZT: Association of HLA-A02 genotype with hepatocellular carcinoma in a prevalent area of China. Chin J Immunol. 15:305–310. 1999.
6	Cai SL, Zhao HT, Leng XS, Cheng TH, Gong SY, Peng JR, Cong X, Wang Y, Rui JA, Hui YZ, Du RY and Chen WF: Melanoma antigen-3 expression in human hepatocellular carcinoma. Chin J Surg. 38:693–696. 2000.PubMed/NCBI
7	Pascolo S, Schirle M, Guckel B, Dumrese T, Stumm S, Kayser S, Moris A, Wallwiener D, Rammensee HG and Stevanovic S: A MAGE-A1 HLA-A*0201 epitope identified by mass spectrometry. Cancer Res. 61:4027–4077. 2001.
8	Vander Bruggen P, Bastin J and Boon T, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A and Boon T: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 24:3038–3043. 1994.
9	Dong HL, Li ZS, Ye J, Qu P, Huang YY, Wu W, Lu SY, Chen GS and Sui YF: Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma. Cancer Biol Ther. 3:891–898. 2004. View Article : Google Scholar : PubMed/NCBI
10	Marchand M, van Baren N, Weynants P, et al: Tumor regression observed in patients with metastic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 80:219–230. 1999. View Article : Google Scholar : PubMed/NCBI
11	Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K and Murai M: Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin Cancer Res. 8:3885–3892. 2002.
12	Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V and Umansky V: Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med. 7:452–458. 2001. View Article : Google Scholar : PubMed/NCBI
13	Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ and Mackall CL: Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol. 38:158–164. 2002. View Article : Google Scholar
14	Schiavetti F, Thonnard J, Colau D, Boon T and Coulie PG: A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res. 62:5510–5516. 2002.PubMed/NCBI
15	Schirle M, Keilholz W, Weber B, Gouttefangeas C, Dumrese T, Becker HD, Stevanović S and Rammensee HG: Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol. 30:2216–2225. 2000. View Article : Google Scholar : PubMed/NCBI
16	Zhang XM, Zhang YF, Huang Y, Qu P, Ma B, Si SY, Li ZS, Li WX, Li X, Ge W, Hu PZ and Sui YF: The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides. Oncol Rep. 20:245–252. 2008.PubMed/NCBI
17	Sidney J, Grey HM, Kubo RT and Sette A: Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today. 17:261–266. 1996. View Article : Google Scholar : PubMed/NCBI